{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=5",
    "query": {
      "condition": "Dermatologic Disorders",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 13595,
    "total_pages": 1360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T10:10:03.729Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04965688",
      "title": "Biology Guided Therapy for Breast Cancer for ER Positive",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Estrogen Receptor-positive Breast Cancer",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Biopsy-Guided Therapy Selection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inova Health Care Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-08-08",
      "completion_date": "2024-03-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-10",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04965688"
    },
    {
      "nct_id": "NCT04317170",
      "title": "Music and Local Anesthesia During Dermatologic Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain",
        "Anxiety"
      ],
      "interventions": [
        {
          "name": "Music",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 100,
      "start_date": "2019-03-21",
      "completion_date": "2020-02-28",
      "has_results": false,
      "last_update_posted_date": "2020-03-23",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04317170"
    },
    {
      "nct_id": "NCT03372941",
      "title": "Hospital Avoidance Strategies for ABSSSI",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Skin Infection"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-03-04",
      "completion_date": "2021-10-14",
      "has_results": true,
      "last_update_posted_date": "2022-12-09",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03372941"
    },
    {
      "nct_id": "NCT02066051",
      "title": "IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "GVHD",
        "Ocular Rosacea",
        "Dry Eye Syndrome"
      ],
      "interventions": [
        {
          "name": "IPL",
          "type": "DEVICE"
        },
        {
          "name": "Meibomian Gland Expression",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 8,
      "start_date": "2013-10",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2015-11-25",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02066051"
    },
    {
      "nct_id": "NCT01875666",
      "title": "Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2013-08-05",
      "completion_date": "2016-12-19",
      "has_results": false,
      "last_update_posted_date": "2020-09-04",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01875666"
    },
    {
      "nct_id": "NCT02905331",
      "title": "Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2017-02-28",
      "completion_date": "2018-02-06",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 8,
      "location_summary": "Ocala, Florida • Rolling Meadows, Illinois • Plainfield, Indiana + 5 more",
      "locations": [
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Rolling Meadows",
          "state": "Illinois"
        },
        {
          "city": "Plainfield",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Fort Gratiot",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02905331"
    },
    {
      "nct_id": "NCT03742986",
      "title": "Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab 360mg",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel 80mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin 60mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 600mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab 8mg/kg and 6 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab 840mg and 420mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2019-05-02",
      "completion_date": "2023-06-12",
      "has_results": true,
      "last_update_posted_date": "2023-12-19",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 2,
      "location_summary": "Bloomington, Indiana • New York, New York",
      "locations": [
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03742986"
    },
    {
      "nct_id": "NCT02865005",
      "title": "Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone 5.0% Gel (SEEGPharm)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Dapsone 5.0% Gel (Allergan)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Seegpharm S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 2361,
      "start_date": "2016-02",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-20",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 35,
      "location_summary": "Encino, California • Fullerton, California • La Mesa, California + 29 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02865005"
    },
    {
      "nct_id": "NCT03317405",
      "title": "Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Carcinoma In Situ",
        "Breast Ductal Carcinoma In Situ",
        "Breast Lobular Carcinoma In Situ",
        "Stage I Breast Cancer AJCC v7",
        "Stage IA Breast Cancer AJCC v7",
        "Stage IB Breast Cancer AJCC v7",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Endoxifen Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2018-10-31",
      "completion_date": "2027-08-12",
      "has_results": true,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03317405"
    },
    {
      "nct_id": "NCT02008994",
      "title": "Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Genomic and Proteomic Profiling",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Sanford Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2013-09",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-10-23T10:10:03.729Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02008994"
    }
  ]
}